BMO Capital Markets reissued their outperform rating on shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) in a report published on Tuesday, June 20th. They currently have a $15.00 price objective on the stock.
Other equities analysts also recently issued research reports about the company. UBS AG downgraded Neos Therapeutics from a buy rating to a neutral rating and set a $8.00 price objective on the stock. in a research note on Friday, March 17th. Zacks Investment Research downgraded Neos Therapeutics from a buy rating to a hold rating in a research note on Saturday, June 10th. ValuEngine upgraded Neos Therapeutics from a strong sell rating to a sell rating in a research note on Thursday, May 18th. Finally, Cowen and Company began coverage on Neos Therapeutics in a research note on Wednesday, April 5th. They issued an outperform rating and a $20.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The company currently has an average rating of Hold and an average price target of $13.00.
Shares of Neos Therapeutics (NASDAQ NEOS) traded down 1.48% during midday trading on Tuesday, hitting $6.65. The stock had a trading volume of 223,234 shares. The firm’s 50-day moving average is $7.57 and its 200 day moving average is $6.90. Neos Therapeutics has a one year low of $4.85 and a one year high of $9.60. The company’s market capitalization is $150.02 million.
Neos Therapeutics (NASDAQ:NEOS) last announced its earnings results on Tuesday, May 9th. The company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.07. Neos Therapeutics had a negative return on equity of 512.10% and a negative net margin of 719.86%. The firm had revenue of $5.63 million for the quarter. Equities analysts expect that Neos Therapeutics will post ($3.24) earnings per share for the current fiscal year.
WARNING: This story was originally posted by BNB Daily and is the property of of BNB Daily. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.baseball-news-blog.com/2017/07/21/bmo-capital-markets-reiterates-outperform-rating-for-neos-therapeutics-inc-neos-updated-updated.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NEOS. UBS Group AG boosted its position in Neos Therapeutics by 6.1% in the first quarter. UBS Group AG now owns 108,714 shares of the company’s stock valued at $783,000 after buying an additional 6,276 shares during the last quarter. Mission Wealth Management LLC purchased a new position in Neos Therapeutics during the first quarter valued at $122,000. Hunter Associates Investment Management LLC purchased a new position in Neos Therapeutics during the first quarter valued at $360,000. Bank of New York Mellon Corp boosted its position in Neos Therapeutics by 37.1% in the first quarter. Bank of New York Mellon Corp now owns 59,841 shares of the company’s stock valued at $431,000 after buying an additional 16,191 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC purchased a new position in Neos Therapeutics during the first quarter valued at $216,000. 33.08% of the stock is currently owned by hedge funds and other institutional investors.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.